Citius Pharmaceuticals, Inc. (CTXR) Ownership
CTXR ownership summary
as of October 18, 2026- Institutions
- 4.9% of shares outstanding
- Insiders
- 1.80% of shares outstanding
- Shares outstanding
- 27.5M
- Float
- 27.0M shares available to trade
- Short interest
- 20.73% 5.6M shares short
- Days to cover
- 28.14 short interest up 0.5% vs prior month
- Institutions 4.85%
- Insiders 1.80%
- Other investors 93.36%
CTXR top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.79% | 216K | $99,147 | −30,621 (−12.4%) | June 30, 2026 |
| 2 | Vanguard Capital Management, LLC | 0.72% | 197K | $90,787 | +29,626 (+17.7%) | June 30, 2026 |
| 3 | Miller Financial Services LLC | 0.47% | 130K | $59,800 | +116,000 (+828.6%) | June 30, 2026 |
| 4 | Citadel Advisors Llc | 0.46% | 125K | $57,459 | +124,910 (0.0%) | June 30, 2026 |
| 5 | Jane Street Group LLC | 0.45% | 123K | $56,505 | +100,314 (+445.4%) | June 30, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 0.28% | 78K | $35,767 | — | June 30, 2026 |
| 7 | BlackRock Inc | 0.25% | 70K | $32,131 | −1 (−0.0%) | June 30, 2026 |
| 8 | Northern Trust Corp | 0.23% | 63K | $28,861 | +18,768 (+42.7%) | June 30, 2026 |
| 9 | XTX Topco Ltd | 0.22% | 59K | $27,232 | +37,904 (+178.0%) | June 30, 2026 |
| 10 | Asset Advisory Group, INC. | 0.21% | 59K | $27,145 | — | June 30, 2026 |
| 11 | BostonPremier Wealth LLC | 0.10% | 28K | $12,880 | +28,000 (0.0%) | June 30, 2026 |
| 12 | UBS Group AG | 0.10% | 26K | $12,114 | −28,690 (−52.1%) | June 30, 2026 |
| 13 | LPL Financial Corp | 0.09% | 25K | $11,705 | +400 (+1.6%) | June 30, 2026 |
| 14 | State Street Corp | 0.08% | 23K | $10,705 | — | June 30, 2026 |
| 15 | Virtu Financial LLC | 0.08% | 21K | $9,585 | +20,836 (0.0%) | June 30, 2026 |
| 16 | Arkadios Wealth Advisors | 0.07% | 20K | $9,200 | — | June 30, 2026 |
| 17 | Two Sigma Investments LLC | 0.06% | 17K | $8,047 | +4,356 (+33.2%) | June 30, 2026 |
| 18 | Sanctuary Advisors, LLC | 0.04% | 12K | $5,433 | +11,810 (0.0%) | June 30, 2026 |
| 19 | Susquehanna International Group, LLP | 0.04% | 12K | $5,426 | −25,043 (−68.0%) | June 30, 2026 |
| 20 | R Squared Ltd | 0.04% | 11K | $5,075 | +11,033 (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 504K shares and 4 cut 84K.
CTXR top mutual fund and ETF holders
3 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.60% | 165K | $75,982 | +26,025 (+18.7%) | August 31, 2026 |
| 2 | Fidelity Series Total Market Index | 0.10% | 26K | $12,125 | — | August 31, 2026 |
| 3 | Fidelity Total Market Index | 0.06% | 15K | $7,034 | +3,636 (+31.2%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
CTXR insider transactions
latest 9| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2019-09-27 | Leonard L Mazur | Buy | $0.90 | 2,234,700 | $2.0M |
| 2019-09-27 | Myron Z Holubiak | Buy | $0.90 | 558,597 | $502,737 |
| 2019-09-25 | Myron Z Holubiak | Buy | $6.02 | 5,000 | $30,100 |
| 2019-04-03 | Leonard L Mazur | Buy | $1.55 | 1,165,048 | $1.8M |
| 2019-04-03 | Myron Z Holubiak | Buy | $1.55 | 129,450 | $200,648 |
| 2018-08-13 | Myron Z Holubiak | Buy | $1.28 | 784,314 | $1.0M |
| 2018-03-28 | Myron Z Holubiak | Buy | $3.09 | 2,915 | $9,007 |
| 2017-08-24 | Leonard L Mazur | Buy | $2.68 | 11,000 | $29,480 |
| 2017-08-08 | Leonard L Mazur | Buy | $4.13 | 421,400 | $1.7M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CTXR shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CTXR
Institutional investors own 4.9% of Citius Pharmaceuticals's shares and insiders 1.80%. The largest holder is Geode Capital Management, LLC with 0.79% of the shares (216K), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 4 reduced their stake in the latest filings. Short interest is 20.73% of the float, or 28.14 days of average trading volume. The share count rose 16,001.3% since 2014.
Related: CTXR analyst forecast, CTXR key metrics. See the CTXR stock overview for the latest quote and news.
CTXR ownership FAQ
Who owns the most Citius Pharmaceuticals stock?
The largest shareholders of Citius Pharmaceuticals are Geode Capital Management, LLC (0.79%), Vanguard Capital Management, LLC (0.72%), Miller Financial Services LLC (0.47%), Citadel Advisors Llc (0.46%), Jane Street Group LLC (0.45%).
What percentage of Citius Pharmaceuticals is owned by institutions?
Institutions hold 4.9% of Citius Pharmaceuticals's shares outstanding; insiders hold 1.80%.
Which funds own Citius Pharmaceuticals?
The largest fund holders of Citius Pharmaceuticals are Fidelity Extended Market Index (0.60%), Fidelity Series Total Market Index (0.10%), Fidelity Total Market Index (0.06%).
What is Citius Pharmaceuticals's short interest?
5.6M shares of Citius Pharmaceuticals were sold short, 20.73% of the float; at the average daily volume it would take 28.14 days to cover.
Are insiders buying or selling Citius Pharmaceuticals?
Of the latest 9 reported insider transactions in Citius Pharmaceuticals (since August 8, 2017), 9 were purchases and 0 were sales.
How many shares of Citius Pharmaceuticals are outstanding?
Citius Pharmaceuticals has 27.5M shares outstanding, of which 27.0M are in the public float.